| Objective Nowadays, the treatment principle for gastric cancer has been changing from mode of surgical dissection to mode of surgical dissection with neoadjuvant chemotherapy and postoperative chemotherapy or targeting therapy, moreover, it is emphasized that standardized dissection and individual chemotherapy performed for patient with gastric cancer, so neoadjuvant chemotherapy becomes one of the most important part of program for gastric cancer. In this thesis, a case control study was performed, and we aimed to explore the clinical value of neoadjuvant chemotherapy by observing its clinical effects for advanced gastric cancer.Method By analyzing retrospectively the 80 advanced gastric cancer cases admitted in gastrointestinal surgery in Qinghai University Affiliated Hospital during October 2013 to October 2014, we set up 40 cases in the surgical group(S Group) and 40 cases in the neoadjuvant chemotherapy group(NCT Group) respectively. Besides, we set 25 FOLFOX6 cases in NCT1 and 15 modified DCF cases in NCT2. Then we make control study of the radical resection rates and postoperative complication rates between S Group and NCT Group. And we also research the clinical effects and the preoperative complications between NCT1 Group and NCT2 Group.Results The results show that the radical resection rate of S Group and NCT Group were 35.0%(14/40) and 60.0%(24/40)respectively, the comparative difference has statistical significance(χ2=5.012,p=0.025); the postoperative complication rates were 45%(18/40)and 42.5%(17/40)respectively, the comparative difference has no statistical significance(χ2=0.051,p=0.822);the clinical total effective rate of the neoadjuvant chemotherapy was 42.5%(17/40); the clinical total effective rates of NCT1 Group and NCT2 Group were 44%(11/25)and 40%(6/15)respectively, the comparative difference has no statistical significance(χ2=0.061,p=0.804); radical resection rate were 64.0%(16/25)and 53.3%(8/15)respectively, there is no statistically significant difference comparing the two groups(χ2=0.444,p=0.505); postoperative complication rates were 44%(11/40)and 40.0%(6/40)respectively, there is no statistically significant difference comparing the two groups(χ2=0.061,p=0.804); adverse reaction rates were 56%(14/25)and 60%(9/15)respectively, there is no statistically significant difference comparing the two groups(χ2=0.061,p=0.804).Conclusion Neoadjuvant chemotherapy can decrease the clinical stage of advanced gastric cancer, shrink tumor volume so as to improve the radical resection and not increase the incidence of postoperative complications. FOLFOX6 and modified DCF can be used as first line of neoadjuvant chemotherapy regimens for advanced gastric cancer. |
PDF Full Text Request